7 assets in EZB-MYC+ Diffuse Large B-Cell Lymphoma

Therapeutic assets addressing EZB-MYC+ Diffuse Large B-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Cyclophosphamide EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Etoposide EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Lenalidomide EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Prednisone EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Rituximab EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
(+)-Vincristine EZB-MYC+ Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)